{"entity":{"id":"qlh12016","kind":"drug","name":"QLH12016","aka":[],"tldr":"QLH12016 is an experimental protein degrader from Qilu Pharmaceutical in phase 2 trials for prostate cancer, aimed at Androgen receptor.","summary":"QLH12016 is a protein degrader developed by Qilu Pharmaceutical. Its target is Androgen receptor. ClinicalTrials.gov describes the intervention as: An oral androgen receptor PROTAC; QLH12016 will be administered orally at the dose and dosing frequency specified in the protocol. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in prostate cancer. The largest, NCT07198633, plans to enrol 212 participants with primary completion expected 2026-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of QLH12016","url":"https://clinicaltrials.gov/search?intr=QLH12016"},{"label":"Sponsor page","url":"https://www.qilu-pharma.com"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":["androgen-receptor"],"drugs":[],"companies":["qilu-pharmaceutical"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07198633"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"protein degrader","mechanism":"Protein degrader directed at Androgen receptor, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/qlh12016/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"target":[{"id":"androgen-receptor","kind":"target","name":"Androgen receptor","route":"/targets/androgen-receptor/"}],"company":[{"id":"qilu-pharmaceutical","kind":"company","name":"Qilu Pharmaceutical","route":"/companies/qilu-pharmaceutical/"}],"trial":[{"id":"nct07198633","kind":"trial","name":"A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer","route":"/trials/nct07198633/"}]}}